Speech-related parameters are sensitive measures of acetylcholinesterase inhibitor therapy in mild Alzheimer's disease – PubMed Black Hawk Supplements

BLACK HAWK: Most trusted ashwagandha supplement for energy

Published article

Our aim was to find out whether speech-related temporal parameters (SRTPs) are sensitive indicators of the clinical outcome in acetylcholinesterase (AChE) inhibitor therapy with donepezil, compared to the standard cognitive Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) used in clinical trials. In this 24-week-long, naturalistic, self-control, open-labeled, prospective pilot study with 10 mg donepezil on 20 mild AD patients, cognitive functions were evaluated using 15…
Black Hawk Supplements, best supplements in the UK

Speech-related parameters are sensitive measures of acetylcholinesterase inhibitor therapy in mild Alzheimer's disease - PubMed

Clinical Trial

Speech-related parameters are sensitive measures of acetylcholinesterase inhibitor therapy in mild Alzheimer’s disease

Éva Hegedűs et al. PLoS One. .

Abstract

Our aim was to find out whether speech-related temporal parameters (SRTPs) are sensitive indicators of the clinical outcome in acetylcholinesterase (AChE) inhibitor therapy with donepezil, compared to the standard cognitive Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) used in clinical trials. In this 24-week-long, naturalistic, self-control, open-labeled, prospective pilot study with 10 mg donepezil on 20 mild AD patients, cognitive functions were evaluated using 15 different SRTPs analyzed by automatic speech recognition in the Speech-Gap Test® compared to ADAS-Cog test results. Among the SRTPs, the filled pause duration ratio significantly improved after 12 weeks of donepezil treatment. During the 24-week follow-up, additional SRTPs such as the filled pause count ratio and the filled pause frequency showed significant benefits. ADAS-Cog total scores showed a slight but not significant improvement compared to baseline after 12 and 24 weeks of donepezil treatment. Among the ADAS-Cog subtests, only orientation improved significantly after 24 weeks of donepezil treatment. Our results indicate that subtle changes in SRTPs measured by the Speech-Gap Test® could be considered as sensitive indicators of the efficacy of the pharmacotherapy in mild AD. According to our data, other cognitive domains did not show improvement in response to donepezil therapy rating by ADAS-Cog. Based on all of this, it is likely that examining and evaluating speech parameters may play an important role in determining the effects of pharmacological treatment of mild AD. The novelty of our study is that it applies the measurement of linguistic parameters as primary outcomes during a drug trial of mild AD in scientific research for the first time.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Cognitive changes due to 24th week donepezil therapy.

A: Significant improvement in ADAS-Cog orientation task at 24th week of donepezil treatment, n = 20; *p = 0.033. B: Significant decrease in duration ratio of filled pause at 12th week and 24th week n = 20;*p = 0.018, furthermore in filled pause count ratio at 24th week n = 20;*p = 0.002, in filled pause frequency n = 20; *p = 0.022 due to donepezil theraphy in mild Alzheimer’s disease patients. Data were analyzed by Friedmann-test and Kendall W coenfficient *<0.05.

References

    1. Kim CK, Lee YR, Ong L, Gold M, Kalali A, Sarkar J. Alzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures. J Alzheimers Dis. 2022; 87(1):83–100. doi: 10.3233/JAD-215699 – DOI – PMC – PubMed
    1. Rosen WG, Mohs RC, Davis KL A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141(11): 1356–1364. doi: 10.1176/ajp.141.11.1356 – DOI – PubMed
    1. Kørner A, Lauritzen L, Bech P. A psychometric evaluation of dementia rating scales. Eur Psychiatry 1996; 11(4): 185–191. doi: 10.1016/0924-9338(96)88389-1 – DOI – PubMed
    1. Petti U, Baker S, Korhonen A. A systematic literature review of automatic Alzheimer’s disease detection from speech and language. J Am Med Inform Assoc 2020; 27(11), 1784–1797. doi: 10.1093/jamia/ocaa174 – DOI – PMC – PubMed
    1. Tóth L, Gosztolya G, Vincze V, Hoffmann I, Szatlóczki G. Automatic detection of mild cognitive impairment from spontaneous speech using ASR. Proceedings of the Annual Conference of the International Speech Communication Association (Interspeech). 2015; 2694–8. doi: 10.21437/Interspeech.2015-568 – DOI

Publication types

MeSH terms

Substances

Grants and funding

The author(s) received no specific funding for this work.

BLACK HAWK: Best lions mane supplement for teens

Read the original publication:

Speech-related parameters are sensitive measures of acetylcholinesterase inhibitor therapy in mild Alzheimer's disease – PubMed